Literature DB >> 28011332

Cardiac complications in cancer treatment - A review.

Xianchi Li1, Min Liu1, Rongrong Sun1, Yi Zeng1, Shuang Chen1, Peiying Zhang2.   

Abstract

Cardiac dysfunction is often associated with effective cancer treatment. A number of targeted therapies against cancer have been observed to cause cardiac dysfunction. In some instances, a patient may outlive his or her cancer but die due to heart failure. Recent research has been focused on the development of new avenues and technological advancements to monitor clinical cardiotoxicity and cardiac dysfunction due to anticancer treatment. These newer treatment options are also increasingly effective and are focused more on post-cancer life. The present review article expands the current view of cardiac complications involved in cancer treatment along with the recent developments in the area.
Copyright © 2017 Hellenic Society of Cardiology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer; Cardiotoxicity; Heart failure; Targeted therapy

Mesh:

Substances:

Year:  2016        PMID: 28011332     DOI: 10.1016/j.hjc.2016.12.003

Source DB:  PubMed          Journal:  Hellenic J Cardiol        ISSN: 1109-9666


  2 in total

1.  Mesenchymal Stem Cell-Derived Small Extracellular Vesicles Protect Cardiomyocytes from Doxorubicin-Induced Cardiomyopathy by Upregulating Survivin Expression via the miR-199a-3p-Akt-Sp1/p53 Signaling Pathway.

Authors:  Ji Yoon Lee; Jihwa Chung; Yeongju Byun; Kyoung Hwa Kim; Shung Hyun An; Kihwan Kwon
Journal:  Int J Mol Sci       Date:  2021-07-01       Impact factor: 5.923

2.  Chrysanthemum morifolium Extract Ameliorates Doxorubicin-Induced Cardiotoxicity by Decreasing Apoptosis.

Authors:  Masaya Ono; Yoichi Sunagawa; Saho Mochizuki; Takahiro Katagiri; Hidemichi Takai; Sonoka Iwashimizu; Kyoko Inai; Masafumi Funamoto; Kana Shimizu; Satoshi Shimizu; Yasufumi Katanasaka; Maki Komiyama; Philip Hawke; Hideo Hara; Yoshiki Arakawa; Kiyoshi Mori; Akira Asai; Koji Hasegawa; Tatsuya Morimoto
Journal:  Cancers (Basel)       Date:  2022-01-28       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.